Biogen to acquire Alcyone Therapeutics for $85m.

Biogen, a global biotechnology company, agreed to acquire Alcyone Therapeutics, a clinical-stage company focused on precision therapies and drug delivery systems, for $85m. “For nearly three decades, Biogen has pioneered ASO development, and we are committed to continuing to improve patient experience and ease of administration. We believe the acquisition of Alcyone Therapeutics offers a strategic opportunity to both expand the company’s capabilities and enhance the value proposition of our medicines by offering a meaningful, patient-centered solution," Nicole Murphy, Biogen Head of Pharmaceutical Operations and Technology.